Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus DEXEDRINE SPANSULE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus DEXEDRINE SPANSULE.
ADDERALL 5 vs DEXEDRINE SPANSULE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Dextroamphetamine is a central nervous system (CNS) stimulant that increases synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting release from presynaptic terminals.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
5-60 mg orally once daily in the morning, using extended-release capsules.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
Terminal elimination half-life is 6-8 hours in adults, 10-13 hours in children, and prolonged in alkaline urine (up to 16-20 hours) due to enhanced tubular reabsorption. In hepatic impairment, half-life may extend to 12-15 hours. Steady-state is reached within 2-3 days.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Renal excretion of unchanged drug (approximately 30-40% unchanged) and hepatic metabolism to inactive metabolites (primarily hippuric acid, benzoic acid, and hydroxylated derivatives). About 90% of a dose is excreted in urine within 48 hours, with 10-15% as unchanged dextroamphetamine; minor biliary/fecal elimination (<5% total).
Category C
Category C
CNS Stimulant
CNS Stimulant